Seagate's Hyperscaler Validation Bolsters Mozaic Execution, But Valuation Risk Persists

What happened

Seagate announced expanded interoperability of its high-capacity HAMR+SMR drives with Broadcom controllers, validated in Microsoft Azure hyperscale environments, reinforcing technical execution of its Mozaic platform. This development aligns with the company's stated momentum, where Mozaic 4 is already shipping in volume to two hyperscalers and management expects it to become the majority of HAMR exabytes exiting CY2026. However, the core investment debate remains centered on supply discipline and pricing, with the stock priced at 95.8x P/E and 112.4x EV/EBITDA based on near-peak margins and allocation through CY2026. The news does not address the risk that hyperscaler capex timing could shift or that discounting could resume as supply loosens, as evidenced by sales incentives at ~10% of gross revenue. Therefore, while this validation supports the bull case for Mozaic execution, it does not mitigate the report's potential sell thesis given limited margin of safety.

Implication

The Broadcom and Azure validation suggests Seagate's HAMR+SMR drives are meeting hyperscaler requirements, which could support near-term revenue per TB and supply efficiency. However, the stock's valuation already embeds successful execution and sustained allocation, leaving little room for error if pricing power wanes. The next earnings reports will be critical to confirm that sales incentives remain near 10% and that data-center revenue per TB continues to rise, as any reversal would signal oversupply. Given the potential sell rating and high valuation, investors should consider trimming positions above $1,100 and only re-enter around $850 if allocation and pricing hold. Monitoring Mozaic 4 ramp progress and hyperscaler capex commitments will be key to adjusting the thesis.

Thesis delta

The announcement of Broadcom interoperability and Azure validation strengthens the bull case for Mozaic 4 technical execution, but does not alter the core thesis that STX is overvalued at $1,031. The risks of allocation ending and discounting rising remain unchanged, and the stock still trades at a premium that assumes flawless execution. Therefore, the potential sell rating remains intact, with the positive news slightly reducing near-term execution risk but not enough to change the risk/reward.